Bantam Pharmaceutical Initiates First-in-Class BTM-3566 Phase 1 Trial for Aggressive Cancers
核心洞察
Bantam Pharmaceutical (搜索) has treated the first patient with BTM-3566 at Princess Margaret Cancer Centre in Toronto, marking a pivotal milestone for this first-in-class mitochondrial-targeting therapy.
BTM-3566 activates the OMA1-ATF4 (搜索) integrated stress response pathway to trigger cancer cell death, offering a novel approach for patients whose cancers no longer respond to standard treatments.
The Phase 1 program spans both U.S. and Canada, studying BTM-3566 in relapsed/refractory B-cell lymphomas (搜索) and various solid tumors including head and neck, lung, and colorectal cancers.
Bantam Pharmaceutical (搜索) has achieved a significant clinical milestone by treating the first patient with BTM-3566 at The Princess Margaret Cancer Centre in Toronto, Canada. This marks the initiation of a Phase 1 clinical trial for the company's first-in-class small molecule designed to target aggressive cancers (搜索) through a novel mitochondrial mechanism.
BTM-3566 represents a paradigm shift in cancer treatment by activating the OMA1-ATF4 (搜索) integrated stress response (ISR) pathway, a newly described mechanism that governs mitochondrial homeostasis and cellular stress responses. Unlike conventional therapies that target specific tumor mutations, this approach harnesses the cancer cell's own machinery to trigger intrinsic apoptotic pathways, making it particularly suited for patients whose cancers have progressed beyond standard treatments.
"Enrolling the first patient in our Phase 1 trial is a pivotal milestone in our clinical development efforts," said Michael Stocum, President & CEO of Bantam Pharmaceutical (搜索). "Princess Margaret Cancer Centre is an esteemed institution, and we are proud to collaborate with their expert investigators to advance this study for patients with limited treatment options."
Novel Mechanism of Action
BTM-3566's unique approach centers on modulating mitochondrial function rather than targeting individual proteins and their cancer-driver mutations. By activating the OMA1-ATF4 (搜索) ISR pathway, the drug specifically uses the machinery of cancer cells to trigger cell death, positioning it as an ideal treatment option for patients whose cancers no longer respond to standard therapies.
Dr. Albiruni Razak, Medical Oncology Lead, Sarcoma at the Princess Margaret Cancer Centre, emphasized the significance of this novel therapeutic approach: "Princess Margaret Cancer Centre is excited to be the first institution to enroll a patient in Bantam's study of this novel therapeutic approach for those who no longer respond to standard treatments."
Comprehensive Clinical Program
The Phase 1 program operates across both the United States and Canada, studying BTM-3566 in two distinct patient populations. The lymphoma cohort focuses on patients with relapsed/refractory mature B-cell lymphomas (搜索), while the solid tumor cohort encompasses a broad range of cancers including head and neck, lung, gastroesophageal/gastrointestinal, colorectal, sarcomas (搜索), uterine, renal and bladder cancers.
Bantam expects to release early information from the first patient during J.P. Morgan Week in January 2026, alongside a comprehensive summary of all non-clinical monotherapy and combination data supporting its regulatory filings in the US and Canada.
Promising Preclinical Results
The clinical advancement of BTM-3566 is supported by robust preclinical data demonstrating potent anti-cancer activity. In patient-derived xenograft (PDX) models of aggressive B-cell lymphomas (搜索), including double- and triple-hit diffuse large B-cell lymphoma (搜索) (DLBCL), BTM-3566 achieved complete tumor regressions. Notably, the drug showed efficacy in mantle cell lymphoma (搜索) (MCL) PDX models derived from patient tumors that had progressed on rituximab, BTK inhibitors, and CAR-T therapies.
The compound also demonstrated activity across solid tumors, producing tumor regressions in multiple PDX models. Low FAM210B (搜索) RNA expression has emerged as a potential biomarker for patient selection in solid tumor applications.
Combination Potential
BTM-3566 exhibits strong synergistic effects when combined with other therapeutic agents, including BH3 mimetics, hypomethylating agents, and rituximab. This versatility enables both monotherapy and combination development strategies, potentially expanding treatment options for patients with limited alternatives.
The ongoing trials can be accessed through ClinicalTrials.gov (NCT06792734 and NCT07266285 for U.S. studies) and ISRCTN.com (ISRCTN15438979 for the Canadian trial). Bantam Pharmaceutical (搜索) currently holds active Investigational New Drug (IND) applications in the U.S. and a Clinical Trial Application (CTA) in Canada for BTM-3566, targeting B-cell malignancies and select solid tumors.